跳至主要内容
临床试验/JPRN-jRCT1080221825
JPRN-jRCT1080221825已完成4 期

Open-Label access Protocol of Denosumab for Subjects with Advanced Cancer

DAIICHISANKYO Co.,Ltd.0 个研究点目标入组 129 人开始时间: 2012年6月14日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
129

研究概览

简要总结

This trial will facilitate access to denosumab for adults with advanced cancer who have participated in a denosumab phase 3 study until denosumab is approved and available for sale.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 18age old 至 ot applicable(—)
性别
All

入选标准

  • Subject was previously enrolled in a denosumab phase 3 study and participated in the Open-label Extension portion of that study.
  • -Subject or subject's legally acceptable representative has provided informed consent.

排除标准

  • -Subject is of child bearing potential and planning to become pregnant within 7 months after the end of treatment.
  • -Subject is of child bearing potential and is not willing to use, in combination with her partner, two highly effective methods of contraception during treatment and for 7 months after the end of treatment.
  • -Subject has known sensitivity to any of the products to be administered during dosing.
  • -Subject will not be available for protocol required study visits or procedures, to the best of the subject and investigator's knowledge.
  • -Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures.

研究者

发起方
DAIICHISANKYO Co.,Ltd.

相似试验

已完成
3 期
Open-Label Access Protocol of Denosumab for Subjects With Advanced CancerBone Metastases in Men With Hormone-Refractory Prostate CancerBone Metastases in Subjects With Advanced Breast Cancer
NCT01419717Amgen129
进行中(未招募)
1 期
Open-Label Access Protocol of Denosumab for Subjects with Advanced CancerBone Metastases in Subjects with Advanced Breast Cancer and Bone Metastases in Men with Hormone-Refractory Prostate CancerMedDRA version: 14.1 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864MedDRA version: 14.1 Level: LLT Classification code 10005993 Term: Bone metastases System Organ Class: 100000004864MedDRA version: 14.1 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 100000004864
EUCTR2011-002114-36-BEAmgen Inc129
进行中(未招募)
不适用
Open-Label Access Protocol of Denosumab for Subjects with Advanced CancerBone Metastases in Subjects with Advanced Breast Cancer and Bone Metastases in Men with Hormone-Refractory Prostate CancerMedDRA version: 16.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: LLTClassification code 10005993Term: Bone metastasesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2011-002114-36-LTAmgen Inc168
进行中(未招募)
1 期
Open-Label Access Protocol of Denosumab for Subjects with Advanced CancerBone Metastases in Subjects with Advanced Breast Cancer and Bone Metastases in Men with Hormone-Refractory Prostate CancerMedDRA version: 16.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0 Level: LLT Classification code 10005993 Term: Bone metastases System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2011-002114-36-HUAmgen Inc129
进行中(未招募)
3 期
Clinical trial to evaluate the efficacy of drug product Denosumab in patients with advance cancer.
CTRI/2012/10/003055Amgen Technology Pvt Ltd400